Novavax and Sanofi Announce Co-exclusive Licensing Settlement to Co-commercialize COVID-19 Vaccine and Broaden Novel COVID-19-Influenza Mixture Vaccines – Would possibly 10, 2024
Settlement supplies folks with broader get right of entry to to a protein-based non-mRNA adjuvanted COVID-19 vaccine via mixed industrial power, from 2025 onwardsProvides Novavax with money and an fairness funding totalling